Teleflex Incorporated (TFX) to Post Q1 2018 Earnings of $2.00 Per Share, Leerink Swann Forecasts

Teleflex Incorporated (NYSE:TFX) – Analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for shares of Teleflex in a research note issued to investors on Tuesday, Zacks Investment Research reports. Leerink Swann analyst R. Newitter forecasts that the medical technology company will post earnings per share of $2.00 for the quarter. Leerink Swann also issued estimates for Teleflex’s Q2 2018 earnings at $2.40 EPS, Q3 2018 earnings at $2.52 EPS and Q4 2018 earnings at $2.67 EPS.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. The firm had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The business’s revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.80 earnings per share.

Several other equities analysts also recently commented on the company. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Deutsche Bank downgraded Teleflex from a “buy” rating to a “hold” rating and set a $251.00 target price on the stock. in a research report on Tuesday, November 14th. Piper Jaffray Companies initiated coverage on Teleflex in a research report on Friday, November 10th. They issued an “overweight” rating and a $295.00 target price on the stock. Morgan Stanley increased their price target on Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Finally, Jefferies Group increased their price target on Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $274.44.

Shares of Teleflex (TFX) traded up $2.59 during midday trading on Thursday, reaching $263.18. The company’s stock had a trading volume of 177,527 shares, compared to its average volume of 276,821. The firm has a market capitalization of $11,860.00, a P/E ratio of 47.51, a PEG ratio of 1.92 and a beta of 1.09. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. Teleflex has a 1 year low of $162.79 and a 1 year high of $271.23.

Large investors have recently made changes to their positions in the stock. Federated Investors Inc. PA raised its position in Teleflex by 65.4% during the 2nd quarter. Federated Investors Inc. PA now owns 38,160 shares of the medical technology company’s stock worth $7,928,000 after purchasing an additional 15,091 shares during the last quarter. Legal & General Group Plc raised its position in Teleflex by 25.6% during the 2nd quarter. Legal & General Group Plc now owns 85,403 shares of the medical technology company’s stock worth $17,734,000 after purchasing an additional 17,403 shares during the last quarter. Clinton Group Inc. bought a new position in Teleflex during the 2nd quarter worth $325,000. Koch Industries Inc. raised its position in Teleflex by 47,174.3% during the 2nd quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock worth $955,000 after purchasing an additional 957,639 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Teleflex during the 3rd quarter worth $955,000. 89.29% of the stock is owned by institutional investors and hedge funds.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total value of $49,792.00. Following the completion of the transaction, the director now directly owns 8,080 shares in the company, valued at approximately $2,011,596.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Benson Smith sold 2,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $258.10, for a total value of $516,200.00. Following the transaction, the chief executive officer now directly owns 76,634 shares of the company’s stock, valued at $19,779,235.40. The disclosure for this sale can be found here. Insiders have sold 2,600 shares of company stock valued at $666,492 over the last 90 days. Corporate insiders own 2.39% of the company’s stock.

The firm also recently announced a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Wednesday, November 15th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Tuesday, November 14th. Teleflex’s payout ratio is presently 24.55%.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/14/teleflex-incorporated-tfx-to-post-q1-2018-earnings-of-2-00-per-share-leerink-swann-forecasts.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply